140 studies found for:    Pituitary Tumors
Show Display Options
Rank Status Study
21 Recruiting Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
Condition: Pituitary Tumor
Intervention:
22 Recruiting Characterization of Receptors in Non-functioning Pituitary Macroadenomas
Condition: Pituitary Tumor
Intervention: Other: To perform RT-PCR on the tissue obtained during surgery
23 Recruiting Evaluation of Patients With Thyroid Disorders
Conditions: Hyperthyroidism;   Hypothyroidism;   Pituitary Neoplasm
Intervention:
24 Enrolling by invitation Rhinological Outcomes in Endonasal Pituitary Surgery
Conditions: Pituitary Neoplasm;   Pituitary Adenoma;   Prolactinoma;   Cushings Disease;   Acromegaly
Intervention:
25 Recruiting The Treatment and Natural History of Acromegaly
Conditions: Acromegaly;   Pituitary Neoplasm
Intervention:
26 Recruiting Proton Radiation Therapy for Pituitary Adenoma
Condition: Pituitary Adenoma
Intervention:
27 Completed
Has Results
Barrow Nasal Inventory Survey
Condition: Pituitary Tumors
Intervention:
28 Completed Effect of 5 Years of GH Replacement on Atherosclerosis
Conditions: Hypopituitarism;   Pituitary Tumors;   Growth Hormone Deficiency
Intervention: Drug: Recombinant Growth Hormone, Genotropin (Pfizer)
29 Recruiting Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Conditions: Healthy;   Pituitary Disease;   Thyroid Disease
Intervention: Drug: TRH (Thyrotropin Releasing Hormone)
30 Recruiting Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly;   Gigantism;   Familial Isolated Pituitary Adenoma;   FIPA;   Pituitary Adenoma Predisposition;   PAP
Intervention:
31 Terminated Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood Infratentorial Ependymoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Gonadotroph Adenoma;   Pituitary Basophilic Adenoma;   Pituitary Chromophobe Adenoma;   Pituitary Eosinophilic Adenoma;   Prolactin Secreting Adenoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Pituitary Tumor;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   TSH Secreting Adenoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: dexamethasone
32 Recruiting A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Condition: Acromegaly
Intervention: Drug: lanreotide
33 Completed Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Conditions: Brain and Central Nervous System Tumors;   Breast Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Lymphoma;   Melanoma (Skin);   Neoplastic Syndrome
Intervention: Radiation: yttrium Y 90-edotreotide
34 Completed Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Conditions: Brain and Central Nervous System Tumors;   Metastatic Cancer;   Radiation Toxicity
Intervention: Other: Questionnaire
35 Active, not recruiting Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Conditions: Pancreatic Neoplasm;   Pituitary Neoplasm;   Nelson Syndrome;   Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
36 Completed Evaluation of Factors in Human Brain Tumors
Conditions: Brain Neoplasm;   Glioblastoma;   Glioma;   Pituitary Neoplasm
Intervention:
37 Completed Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
Conditions: Acromegaly;   Pituitary Neoplasm
Intervention: Drug: Sandostatin LAR Depot versus transsphenoidal surgery
38 Recruiting A Prospective Study of Outcome After Therapy for Acromegaly
Condition: Acromegaly
Intervention:
39 Completed
Has Results
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Condition: Acromegaly
Intervention: Drug: Lanreotide autogel 120 mg
40 Recruiting Tegaderm and Visual Evoked Potentials
Condition: Tumor of Pituitary and Suprasellar Region
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years